Methacrylic Acid

Methacrylic Acid

SCHEMBL2639348

C=C(C)C(=O)O.C=C(C)COCCP(=O)(O)O

nearest known ligand 0.33

Full drug profile on Sugi Atlas →

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
BTN3A1 O00481 1/20 0.33
PEPD P12955 1/20 0.31
THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4272527 0.91 BTN3A1 (0.37) BTN3A1
SCHEMBL1369448 0.79 TYMS (0.42) BTN3A1
SCHEMBL632959 0.79 PEPD (0.34) PEPD
SCHEMBL1557153 0.79 BTN3A1 (0.37) BTN3A1
Methacrylic Acid SCHEMBL2639351 0.76 THRB (0.47) BTN3A1PEPDTHRB
Methacrylic Acid SCHEMBL491387 0.74 BLM (0.39) THRB
Diethylamine SCHEMBL6858469 0.73 SAT1 (0.31)
Methacrylic Acid SCHEMBL21049927 0.72 LPAR3 (0.43)
SCHEMBL1557385 0.72 GABBR2 (0.35) BTN3A1
SCHEMBL5604146 0.72 BTN3A1 (0.32) BTN3A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4791042-B2 2011-10-12 JP claimed
EP-1401562-B1 PROCESS FOR THE FORMATION OF EMULSIONS SYNGENTA LTD (GB) 2008-10-08 EP claimed
US-7199185-B2 Use of reactive polymeric surfactants in the formation of emulsions SYNGENTA LIMITED (GB) 2007-04-03 US claimed
EP-1569512-B1 PARTICULATE SUSPENSIONS SYNGENTA LTD (GB) 2007-02-28 EP claimed
US-20060116290-A1 Particulate suspensions SYNGENTA CROP PROTECTION, INC. 2006-06-01 US claimed
EP-1569512-A2 PARTICULATE SUSPENSIONS Syngenta Limited (GB) 2005-09-07 EP claimed
US-20040197357-A1 Use of reactive polymeric surfactants in the formation of emulsions SYNGENTA LIMITED (GB) 2004-10-07 US claimed
WO-2004052099-A2 PARTICULATE SUSPENSIONS SYNGENTA LIMITED (GB) 2004-06-24 WO claimed
EP-1401562-A2 USE OF REACTIVE POLYMERIC SURFACTANTS IN THE FORMATION OF EMULSIONS Syngenta Limited (GB) 2004-03-31 EP claimed
WO-2002100525-A2 USE OF REACTIVE POLYMERIC SURFACTANTS IN THE FORMATION OF EMULSIONS SYNGENTA LIMITED (GB) 2002-12-19 WO claimed
EP-1401562-B1 PROCESS FOR THE FORMATION OF EMULSIONS SYNGENTA LTD (GB) 2008-10-08 EP disclosed
US-7199185-B2 Use of reactive polymeric surfactants in the formation of emulsions SYNGENTA LIMITED (GB) 2007-04-03 US disclosed
EP-1569512-B1 PARTICULATE SUSPENSIONS SYNGENTA LTD (GB) 2007-02-28 EP disclosed
US-20060116290-A1 Particulate suspensions SYNGENTA CROP PROTECTION, INC. 2006-06-01 US disclosed
EP-1569512-A2 PARTICULATE SUSPENSIONS Syngenta Limited (GB) 2005-09-07 EP disclosed
US-20040197357-A1 Use of reactive polymeric surfactants in the formation of emulsions SYNGENTA LIMITED (GB) 2004-10-07 US disclosed
WO-2004052099-A2 PARTICULATE SUSPENSIONS SYNGENTA LIMITED (GB) 2004-06-24 WO disclosed
EP-1401562-A2 USE OF REACTIVE POLYMERIC SURFACTANTS IN THE FORMATION OF EMULSIONS Syngenta Limited (GB) 2004-03-31 EP disclosed
WO-2002100525-A2 USE OF REACTIVE POLYMERIC SURFACTANTS IN THE FORMATION OF EMULSIONS SYNGENTA LIMITED (GB) 2002-12-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040197357-A1 Use of reactive polymeric surfactants in the formation of emulsions PHOSPHO1, APOB, LIPA BTN3A1 2256/4885PEPD 3476/4885THRB 2972/4885
US-20060116290-A1 Particulate suspensions PFAS, VCL, JMJD7 BTN3A1 3199/4885PEPD 962/4885THRB 4740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.